Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 11/20 | 0.54 |
| ▸ | ITGAV | P06756 | 11/20 | 0.54 |
| ▸ | ITGA2B | P08514 | 7/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7216459 | 0.89 | ITGB3 (0.66) | ITGB3ITGAVITGA2BLMNAGAA | |
| SCHEMBL7392649 | 0.84 | ITGB3 (0.74) | ITGB3ITGAVITGA2B | |
| SCHEMBL7211723 | 0.84 | ITGB3 (0.74) | ITGB3ITGAVITGA2B | |
| SCHEMBL7211729 | 0.82 | ITGB3 (0.55) | ITGB3ITGAVITGA2BPOLB | |
| SCHEMBL7211510 | 0.82 | ITGB3 (0.52) | ITGB3ITGAVITGA2BLMNAGAA | |
| SCHEMBL7217699 | 0.78 | ITGB3 (0.51) | ITGB3ITGAVITGA2BLMNAPOLB | |
| SCHEMBL7212645 | 0.75 | ITGB3 (0.60) | ITGB3ITGAVITGA2BLMNAPOLB | |
| SCHEMBL7216485 | 0.75 | ITGB3 (0.86) | ITGB3ITGAVITGA2B | |
| SCHEMBL7216428 | 0.74 | ITGB3 (0.61) | ITGB3ITGAVITGA2BLMNAPOLB | |
| SCHEMBL7217497 | 0.73 | ITGB3 (0.92) | ITGB3ITGAVITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6620820-B2 | Imidazole dione or one, thione derivatives as antitumor and antiinflammatory agents, also treats cardiovascular disease, nephropathies and retinopathies | HOECHST AKTIENGESELLSCHAFT (DE) | 2003-09-16 | — | — | US | disclosed |
| US-20020119999-A1 | Novel inhibitors of bone reabsorption and antagonists of vitronectin receptors | HOECHST AKTIENGESELLSCHAFT | 2002-08-29 | — | — | US | disclosed |
| US-6218415-B1 | THERAPY OF BONE REABSORPTION BY OSTEOCLASTS, TUMOR GROWTH AND TUMOR METASTASIS, INFLAMMATION, CARDIOVASCULAR DISEASE, NEPHROPATHIES AND RETINOPATHIES | HOECHST AKTIENGESELLSCHAFT (DE) | 2001-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119999-A1 | Novel inhibitors of bone reabsorption and antagonists of vitronectin receptors | ADGRF1, CALCR, SOST | ITGB3 500/4885ITGAV 478/4885ITGA2B 534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.